Who are Injection of Onabotulinum toxin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botox, Botulinum Toxin Type A 900kD, OnabotulinumtoxinA 145 UNT [Botox], Botulinum Toxin-A injection, Abobotulinum toxin A, Onabotulinumtoxin A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/injection-of-onabotulinum-toxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Injection of Onabotulinum toxin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Injection of Onabotulinum toxin (Injection of Onabotulinum toxin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology.

phase 2 Botulinum toxin SNAP-25 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Injection of Onabotulinum toxin (Injection of Onabotulinum toxin) — Swiss Paraplegic Research, Nottwil. Blocks acetylcholine release at neuromuscular junctions

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Injection of Onabotulinum toxin TARGET	Injection of Onabotulinum toxin	Swiss Paraplegic Research, Nottwil	phase 2	Botulinum toxin	SNAP-25
Botox	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Botulinum Toxin Type A 900kD	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 145 UNT [Botox]	OnabotulinumtoxinA 145 UNT [Botox]	Beth Israel Deaconess Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)
Abobotulinum toxin A	Abobotulinum toxin A	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A	Onabotulinumtoxin A	Wake Forest University Health Sciences	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Injection of Onabotulinum toxin — Competitive Intelligence Brief. https://druglandscape.com/ci/injection-of-onabotulinum-toxin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab